[go: up one dir, main page]

CL2014000175A1 - Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. - Google Patents

Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.

Info

Publication number
CL2014000175A1
CL2014000175A1 CL2014000175A CL2014000175A CL2014000175A1 CL 2014000175 A1 CL2014000175 A1 CL 2014000175A1 CL 2014000175 A CL2014000175 A CL 2014000175A CL 2014000175 A CL2014000175 A CL 2014000175A CL 2014000175 A1 CL2014000175 A1 CL 2014000175A1
Authority
CL
Chile
Prior art keywords
oxo
compound
cancer
benzazepin
butanamide
Prior art date
Application number
CL2014000175A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2014000175A1 publication Critical patent/CL2014000175A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2014000175A 2011-07-27 2014-01-23 Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. CL2014000175A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
CL2014000175A1 true CL2014000175A1 (es) 2014-08-22

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000175A CL2014000175A1 (es) 2011-07-27 2014-01-23 Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.

Country Status (36)

Country Link
US (1) US8569286B2 (es)
EP (1) EP2736920B1 (es)
JP (1) JP6027110B2 (es)
KR (1) KR101578309B1 (es)
CN (1) CN103732612B (es)
AP (1) AP4080A (es)
AR (1) AR087107A1 (es)
AU (1) AU2012287251B2 (es)
BR (1) BR112014001600B1 (es)
CA (1) CA2841178C (es)
CL (1) CL2014000175A1 (es)
CO (1) CO6862159A2 (es)
CR (1) CR20140036A (es)
CY (1) CY1116645T1 (es)
DK (1) DK2736920T3 (es)
DO (1) DOP2014000011A (es)
EA (1) EA023044B1 (es)
EC (1) ECSP14013179A (es)
ES (1) ES2544937T3 (es)
GT (1) GT201400012A (es)
HR (1) HRP20150771T1 (es)
HU (1) HUE027534T2 (es)
IL (1) IL229988A (es)
JO (1) JO3148B1 (es)
MA (1) MA35611B1 (es)
ME (1) ME02171B (es)
MX (1) MX356536B (es)
MY (1) MY184303A (es)
PE (1) PE20141061A1 (es)
PH (1) PH12014500215B1 (es)
PL (1) PL2736920T3 (es)
PT (1) PT2736920E (es)
RS (1) RS54135B1 (es)
SI (1) SI2736920T1 (es)
TW (1) TWI568730B (es)
WO (1) WO2013016081A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
CN118994191A (zh) 2016-02-05 2024-11-22 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
WO2017180385A1 (en) * 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
ES2881801T3 (es) * 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
CA3025024A1 (en) * 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
KR102512899B1 (ko) * 2016-08-31 2023-03-23 일라이 릴리 앤드 캄파니 고형 종양의 치료를 위한 투약 요법
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
HRP20220636T1 (hr) 2016-12-09 2022-07-22 Denali Therapeutics Inc. Spojevi korisni kao inhibitori ripk1
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
SG11202003427XA (en) * 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
KR20210005714A (ko) * 2018-05-06 2021-01-14 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
US20220192984A1 (en) 2018-10-02 2022-06-23 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
CA3136424A1 (en) 2019-04-08 2020-10-15 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3812952B2 (ja) * 1996-12-23 2006-08-23 エラン ファーマシューティカルズ，インコーポレイテッド シクロアルキル、ラクタム、ラクトンおよびその関連化合物およびその医薬組成物、並びに該化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法
EP1089980A1 (en) * 1998-06-22 2001-04-11 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO1999067219A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
NZ541324A (en) 2003-02-04 2008-10-31 Hoffmann La Roche Malonamide derivatives as gamma-secretase inhibitors
DE602004020680D1 (de) 2003-09-09 2009-05-28 Hoffmann La Roche Die aktivität von gamma-secretase blockierende malonamidderivate
KR100867035B1 (ko) 2003-10-06 2008-11-04 에프. 호프만-라 로슈 아게 감마-세크레타제 저해제로서 유용한 치환된다이벤조-아제핀 및 벤조-다이아제핀 유도체
EP2018368B1 (en) 2006-03-27 2012-12-05 F. Hoffmann-La Roche AG Malonamide derivatives as gamma secretase inhibitors
BRPI0807341A2 (pt) * 2007-02-02 2014-05-20 Hoffmann La Roche Derivados de 6-oxo-6,7-di-hidro-5h-dibenzo[b,d]azepin-7-ila
BRPI0906831A2 (pt) 2008-01-11 2019-09-24 Hoffmann La Roche uso de um inibidor de gama-secretase para tratamento de câncer
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
EP2736920B1 (en) 2015-07-01
JP6027110B2 (ja) 2016-11-16
US20130029972A1 (en) 2013-01-31
ME02171B (me) 2015-10-20
MX356536B (es) 2018-06-01
CA2841178C (en) 2016-12-20
RS54135B1 (sr) 2015-12-31
CN103732612B (zh) 2015-09-23
TWI568730B (zh) 2017-02-01
KR101578309B1 (ko) 2015-12-16
HUE027534T2 (en) 2016-11-28
BR112014001600A2 (pt) 2017-02-21
MA35611B1 (fr) 2014-11-01
IL229988A (en) 2017-07-31
CY1116645T1 (el) 2017-03-15
PL2736920T3 (pl) 2015-11-30
ECSP14013179A (es) 2014-03-31
BR112014001600B1 (pt) 2022-09-13
AP4080A (en) 2017-03-29
PE20141061A1 (es) 2014-09-06
PT2736920E (pt) 2015-09-16
NZ618891A (en) 2015-12-24
TW201315732A (zh) 2013-04-16
DK2736920T3 (en) 2015-07-20
CN103732612A (zh) 2014-04-16
AU2012287251B2 (en) 2015-05-14
HK1194086A1 (en) 2014-10-10
SI2736920T1 (sl) 2015-08-31
GT201400012A (es) 2014-07-16
KR20140026624A (ko) 2014-03-05
JO3148B1 (ar) 2017-09-20
MX2014001084A (es) 2014-02-27
AR087107A1 (es) 2014-02-12
CA2841178A1 (en) 2013-01-31
EA023044B1 (ru) 2016-04-29
EA201490161A1 (ru) 2014-04-30
PH12014500215B1 (en) 2018-09-07
ES2544937T3 (es) 2015-09-07
CR20140036A (es) 2014-03-21
HRP20150771T1 (hr) 2015-08-28
PH12014500215A1 (en) 2014-03-17
EP2736920A1 (en) 2014-06-04
WO2013016081A1 (en) 2013-01-31
AP2014007362A0 (en) 2014-01-31
DOP2014000011A (es) 2014-07-31
MY184303A (en) 2021-03-31
AU2012287251A1 (en) 2014-01-30
CO6862159A2 (es) 2014-02-10
JP2014527042A (ja) 2014-10-09
US8569286B2 (en) 2013-10-29

Similar Documents

Publication Publication Date Title
CL2014000175A1 (es) Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CL2009000448A1 (es) Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
MY177344A (en) Compounds and their methods of use
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
CO6700837A2 (es) Proceso de elaboración para derivados de prrimidina
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
PH12015501609A1 (en) Phenicol antibacterials
PH12018500071A1 (en) Plinabulin compositions
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
TW201613864A (en) Novel compounds
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion
UA115357C2 (uk) Похідні піридин-4-ілу
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
CL2014001323A1 (es) Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
WO2014115169A3 (en) Crizotinib solid dispersion
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug